{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:13:13Z","timestamp":1761109993722},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,2,12]],"date-time":"2011-02-12T00:00:00Z","timestamp":1297468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00259-011-1744-x","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T16:52:56Z","timestamp":1297443176000},"page":"1270-1280","source":"Crossref","is-referenced-by-count":58,"title":["Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts"],"prefix":"10.1007","volume":"38","author":[{"given":"Stephan","family":"Walrand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Barone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Jamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,12]]},"reference":[{"key":"1744_CR1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ejca.2005.12.020","volume":"42","author":"B Brans","year":"2006","unstructured":"Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. Eur J Cancer 2006;42:994\u20131003.","journal-title":"Eur J Cancer"},{"key":"1744_CR2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1078\/0939-3889-00291","volume":"16","author":"G Flux","year":"2006","unstructured":"Flux G, Bardies M, Monsieurs M, Savolainen S, Strand SE, Lassmann M, et al. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys 2006;16:47\u201359.","journal-title":"Z Med Phys"},{"key":"1744_CR3","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00259-007-0471-9","volume":"34","author":"G Flux","year":"2007","unstructured":"Flux G, Bardies M, Chiesa C, Monsieurs M, Savolainen S, Strand SE, et al. Clinical radionuclide therapy dosimetry: the quest for the \u201cHoly Gray\u201d. Eur J Nucl Med Mol Imaging 2007;34:1699\u2013700.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1744_CR4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00259-006-0338-5","volume":"34","author":"B Brans","year":"2007","unstructured":"Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, et al. Clinical radionuclide therapy dosimetry: the quest for the \u201cHoly Gray\u201d. Eur J Nucl Med Mol Imaging 2007;34:772\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1744_CR5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.semnuclmed.2008.05.008","volume":"38","author":"G Sgouros","year":"2008","unstructured":"Sgouros G, Frey E, Wahl R, He B, Prideaux A, Hobbs R. Three-dimensional imaging-based radiobiological dosimetry. Semin Nucl Med 2008;38:321\u201334.","journal-title":"Semin Nucl Med"},{"key":"1744_CR6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.semnuclmed.2008.05.005","volume":"38","author":"MG Stabin","year":"2008","unstructured":"Stabin MG, Brill AB. State of the art in nuclear medicine dose assessment. Semin Nucl Med 2008;38:308\u201320.","journal-title":"Semin Nucl Med"},{"key":"1744_CR7","first-page":"99S","volume":"46","author":"R Barone","year":"2005","unstructured":"Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S\u2013106S.","journal-title":"J Nucl Med"},{"key":"1744_CR8","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","volume":"49","author":"BW Wessels","year":"2008","unstructured":"Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response\u2014implications for radionuclide therapy. J Nucl Med 2008;49:1884\u201399.","journal-title":"J Nucl Med"},{"key":"1744_CR9","first-page":"92S","volume":"46","author":"S Pauwels","year":"2005","unstructured":"Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46:92S\u20138S.","journal-title":"J Nucl Med"},{"key":"1744_CR10","first-page":"1467","volume":"47","author":"M Cremonesi","year":"2006","unstructured":"Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467\u201375.","journal-title":"J Nucl Med"},{"key":"1744_CR11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009;36:1138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1744_CR12","first-page":"849","volume":"26","author":"DJ Hnatowich","year":"1985","unstructured":"Hnatowich DJ, Griffin TW, Kosciuczyk C, Rusckowski M, Childs RL, Mattis JA, et al. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J Nucl Med 1985;26:849\u201358.","journal-title":"J Nucl Med"},{"key":"1744_CR13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s002590050366","volume":"26","author":"M Cremonesi","year":"1999","unstructured":"Cremonesi M, Ferrari M, Chinol M, Stabin MG, Grana C, Prisco G, et al. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 1999;26:110\u201320.","journal-title":"Eur J Nucl Med"},{"key":"1744_CR14","first-page":"21","volume":"10","author":"CF Meares","year":"1990","unstructured":"Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshpande SV, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl 1990;10:21\u20136.","journal-title":"Br J Cancer Suppl"},{"key":"1744_CR15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0883-2897(92)90012-N","volume":"19","author":"C Wu","year":"1992","unstructured":"Wu C, Virzi F, Hnatowich DJ. Investigations of N-linked macrocycles for 111In and 90Y labeling of proteins. Int J Rad Appl Instrum B 1992;19:239\u201344.","journal-title":"Int J Rad Appl Instrum B"},{"key":"1744_CR16","first-page":"503","volume":"26","author":"DJ Hnatowich","year":"1985","unstructured":"Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodies labeled with yttrium-90. J Nucl Med 1985;26:503\u20139.","journal-title":"J Nucl Med"},{"key":"1744_CR17","first-page":"38","volume":"37","author":"JMH Klerk de","year":"1996","unstructured":"de Klerk JMH, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med 1996;37:38\u201341.","journal-title":"J Nucl Med"},{"key":"1744_CR18","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0277-5379(91)90297-Q","volume":"27","author":"JH Turner","year":"1991","unstructured":"Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991;27:1084\u20136.","journal-title":"Eur J Cancer"},{"key":"1744_CR19","volume-title":"Radiobiological factors in manned space flight","author":"WH Langham","year":"1967","unstructured":"Langham WH. Radiobiological factors in manned space flight. Washington DC: National Academy Press; 1967."},{"key":"1744_CR20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Lind\u00e9n O, Flux G, EANM Dosimetry Committee, et al. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 2010;37:1238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1744_CR21","doi-asserted-by":"crossref","unstructured":"Lassmann M, Chiesa C, Flux G, Bardi\u00e8s M, EANM Dosimetry Committee, et al. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 2011;38:192\u2013200. doi: 10.1007\/s00259-010-1549-3","DOI":"10.1007\/s00259-010-1549-3"},{"key":"1744_CR22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00259-002-1068-y","volume":"30","author":"S Walrand","year":"2003","unstructured":"Walrand S, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003;30:354\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1744_CR23","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/BF01254478","volume":"23","author":"SH Walrand","year":"1996","unstructured":"Walrand SH, van Elmbt LR, Pauwels S. A non-negative fast multiplicative algorithm in 3D scatter-compensated SPET reconstruction. Eur J Nucl Med 1996;23:1521\u20136.","journal-title":"Eur J Nucl Med"},{"key":"1744_CR24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1088\/0031-9155\/26\/3\/003","volume":"26","author":"M Cristy","year":"1981","unstructured":"Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol 1981;26:389\u2013400.","journal-title":"Phys Med Biol"},{"key":"1744_CR25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/108497802760363213","volume":"17","author":"MG Stabin","year":"2002","unstructured":"Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm 2002;17:427\u201333.","journal-title":"Cancer Biother Radiopharm"},{"key":"1744_CR26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF02990029","volume":"17","author":"WJ Shih","year":"2003","unstructured":"Shih WJ, Van Wyk C. Tc-99m depreotide SPECT demonstrates photon-deficiency in the thoracic vertebrae after adjunct radiation therapy of lung cancer: correlation with MRI and bone scintigraphy. Ann Nucl Med 2003;17:245\u20138.","journal-title":"Ann Nucl Med"},{"key":"1744_CR27","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1007\/s00259-002-1006-z","volume":"30","author":"R Barone","year":"2003","unstructured":"Barone R, Walrand S, Leveque P, Pauwels S, Jamar F. Red marrow toxicity after therapy with radiolabelled somatostatin analogues: a possible role of plasma protein binding. Eur J Nucl Med 2003;30:S232.","journal-title":"Eur J Nucl Med"},{"key":"1744_CR28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1148\/94.3.679","volume":"94","author":"W Hauser","year":"1970","unstructured":"Hauser W, Atkins HL, Nelson KG, Richards P. Technetium-99m DTPA: a new radiopharmaceutical for brain and kidney scanning. Radiology 1970;94:679\u201384.","journal-title":"Radiology"},{"key":"1744_CR29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0047-0740(81)90034-6","volume":"8","author":"SM Moerlein","year":"1981","unstructured":"Moerlein SM, Welch MJ. The chemistry of gallium and indium as related to radiopharmaceutical production. Int J Nucl Med Biol 1981;8:277\u201387.","journal-title":"Int J Nucl Med Biol"},{"key":"1744_CR30","unstructured":"Stern HS, Goodwin DA, Scheffel D, Wagner HN, Kramer HH. In 113m for blood-pool and brain scanning. Nucleonics 1967;25:62\u20138."},{"key":"1744_CR31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/180919b0","volume":"180","author":"H Kroll","year":"1957","unstructured":"Kroll H, Korman S, Siegel E, Hart HE, Rosoff B, Spencer H, et al. Excretion of yttrium and lanthanum chelates of cyclohexane 1,2-trans diamine tetraacetic acid and diethylenetriamine pentaacetic acid in man. Nature 1957;180:919\u201320.","journal-title":"Nature"},{"key":"1744_CR32","first-page":"496","volume":"19","author":"MK Jeffcoat","year":"1978","unstructured":"Jeffcoat MK, McNeil BJ, Davis MA. Indium and iron as tracers for erythroid precursors. J Nucl Med 1978;19:496\u2013500.","journal-title":"J Nucl Med"},{"key":"1744_CR33","unstructured":"Goodwin DA, Sundeberg MW, Diamanti C et al. 111In-labeled radiopharmaceuticals and their clinical use. In: Subramanian G, Rhodes BA, Cooper JF, Sood VJ, editors. Radiopharmaceuticals. New York: The Society of Nuclear Medicine; 1975. p. 80."},{"key":"1744_CR34","unstructured":"Welch MJ, Welch TJ. Solution chemistry of carrier-free indium. In: Subramanian G, Rhodes BA, Cooper JF, Sood VJ, editors. Radiopharmaceuticals. New York: The Society of Nuclear Medicine; 1975. p. 73."},{"key":"1744_CR35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00259-002-1054-4","volume":"30","author":"WP Breeman","year":"2003","unstructured":"Breeman WP, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, et al. The addition of DTPA to [(177)Lu-DOTA(0),Tyr(3)]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging 2003;30:312\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1744_CR36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0301-472X(01)00772-X","volume":"30","author":"SP Oomen","year":"2002","unstructured":"Oomen SP, van Hennik PB, Antonissen C, Lichtenauer-Kaligis EG, Hofland LJ, Lamberts SW, et al. Somatostatin is a selective chemoattractant for primitive (CD34+) hematopoietic progenitor cells. Exp Hematol 2002;30:116\u201325.","journal-title":"Exp Hematol"},{"key":"1744_CR37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ajh.21279","volume":"83","author":"BS Skikne","year":"2008","unstructured":"Skikne BS. Serum transferrin receptor. Am J Hematol 2008;83:872\u20135.","journal-title":"Am J Hematol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-1744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-011-1744-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-1744-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T10:18:44Z","timestamp":1559989124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-011-1744-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,12]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["1744"],"URL":"https:\/\/doi.org\/10.1007\/s00259-011-1744-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,12]]}}}